Biricodar
From Self-sufficiency
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (October 2006) |
| File:Biricodar.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate | |
| Identifiers | |
| CAS Number | 174254-13-8 |
| ATC code | none |
| PubChem | CID 3037617 |
| ChemSpider | 2301309 |
| Chemical data | |
| Formula | C34H41N3O7 |
| Molar mass | 603.705 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
| (verify) | |
Biricodar (INN, codename VX-170, marketed as the dicitrate salt under the trade name Incel) is a pharmaceutical drug released by Vertex Pharmaceuticals in 1999 to help treat ovarian cancer patients.
External links
 |
This medical article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Orphaned articles from October 2006
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Chemotherapeutic agents
- Medicine stubs
- 2Fix
